Cat. No. 3724
Chemical Name: N-[6-(2,6-Dichlorophenyl)-2-[[4-(di
Biological ActivitySelective FGFR inhibitor (IC50 values are 40, 262 and 3700 nM for FGFR, PDGFR and EGFR respectively). Inhibits FGFR receptor phosphorylation (IC50 = 622 nM) and growth of A121 cells in vitro.
Licensing InformationSold for research purposes under agreement from Pfizer Inc.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Stevens et al (2003) Thyroid hormone activates fibroblast growth factor receptor-1 in bone. Mol.Endocrinology 17 1751.
Batley et al (1998) Inhibition of FGF-1 receptor tyrosine kinase activity by PD 161570, a new protein-tyrosine kinase inhibitor. Life Sci. 62 143. PMID: 9488112.
Hamby et al (1997) Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. J.Med.Chem. 40 2296. PMID: 9240345.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for PD 161570 include:
Rodríguez et al (2012) Modulation of pluripotency in the porcine embryo and iPS cells. J Exp Bot 7 e49079. PMID: 23145076.
Do you know of a great paper that uses PD 161570 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: PD 161570, supplier, PD161570, selective, FGFR, inhibitors, inhibits, fibroblast, growth, factors, Pfizer, Tocris Bioscience, FGFR Inhibitor products
Find multiple products by catalog number
New Products in this Area
Selective TrkB receptor agonist; neuroprotectantAV 412
Potent inhibitor of EGFR, ErbB2 and Abl receptor tyrosine kinasesCP 724714
Potent and selective ErbB2 inhibitorMitoglitazone
Insulin sensitizer; exhibits low binding affinity at PPARγPF 6274484
High affinity and potent covalent EGFR kinase inhibitorCanertinib dihydrochloride
Potent EGFR kinase inhibitorCHMFL-FLT3-122
Potent and selective FLT3 inhibitor
October 30 - November 3, 2016
Boston, MA, USA